Takeda
- Health
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
Osaka, Japan & Cambridge, Mass., United States: – Key learnings from real-world data and retrospective studies from nine abstracts are presented…
Read More » -
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the…
Read More » -
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…
Read More » - Health
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting
Osaka, Japan & Cambridge, Mass., United States: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored…
Read More » - Business
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
Osaka, Japan: FY2020 H1 results driven by growth of global brands (e.g. Entyvio +25.8% YOY, TAKHZYRO +45.5% YOY, NINLARO +…
Read More » - Health
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
Osaka, Japan: Three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW) to…
Read More » - Technology
Takeda Accelerates Digital Transformation with Accenture and AWS
Osaka, Japan & Seattle, New York, United States: Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), Accenture (NYSE: ACN) and…
Read More » - Health
Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis
Osaka, Japan: Interim analysis from VISIBLE OLE study showed long-term findings consistent with the known safety profile of vedolizumab with…
Read More » - Health
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress
Osaka, Japan & Cambridge, Mass., United States: − Key Results from Phase 3 ALTA 1L Sub-Analyses Further Support ALUNBRIG’s Strong Intracranial…
Read More » -
Takeda to Divest TachoSil® to Corza Health for €350 Million
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest its…
Read More » - United States
Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma
Osaka, Japan & Cambridge, Mass., United States: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3…
Read More »